

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07C 235/64, A61K 47/48</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/06534</b> <b>(43) International Publication Date:</b> 10 February 2000 (10.02.00)
<b>(21) International Application Number:</b> PCT/US99/17090 <b>(22) International Filing Date:</b> 27 July 1999 (27.07.99)  <b>(30) Priority Data:</b> 60/094,267 27 July 1998 (27.07.98) US 60/104,466 16 October 1998 (16.10.98) US  <b>(71) Applicant (for all designated States except US):</b> EMISPHERE TECHNOLOGIES, INC. [US/US]; 765 Old Saw Mill River Road, Tarrytown, NY 10591 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> LEONE-BAY, Andrea [US/US]; 20 Woodland Way, Ridgefield, CT 06877 (US). O'TOOLE, Doris [US/US]; 33 Lakeview Road, Carmel, NY 10512 (US).  <b>(74) Agents:</b> LESSLER, Jay, P. et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022-7513 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS  <b>(57) Abstract</b>  Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS

### 15 FIELD OF THE INVENTION

The present invention relates to compounds for delivering active agents, and particularly biologically or chemically active agents. These compounds are used as carriers to facilitate the delivery of an active agent to a target. The carrier compounds are well suited to form non-covalent mixtures with biologically-active agents for pulmonary, oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, rectal, vaginal, mucosal, transdermal, intradermal, parenteral, intravenous, and intramuscular administration to animals, as well as crossing the blood-brain barrier. Methods for the preparation and administration of such compositions are also disclosed.

### 25 BACKGROUND OF THE INVENTION

Conventional means for delivering active agents are often severely limited by biological, chemical, and physical barriers. Typically, these barriers are imposed by the environment through which delivery occurs, the environment of the target for delivery, or the target itself. Biologically or chemically active agents are particularly vulnerable to such barriers.

30 For example, in the delivery to animals of biologically active or chemically active pharmacological and therapeutic agents, barriers are imposed by the body. Examples of physical barriers are the skin and various organ membranes that must be traversed before reaching a target. Chemical barriers include, but are not limited to, pH variations, lipid bi-layers, and degrading enzymes.

35 These barriers are of particular significance in the design of drug delivery systems. For example, oral delivery of many biologically or chemically active agents would be alternate

5 routes of choice for administration to animals if not for biological, chemical, and physical barriers such as varying pH in the gastro-intestinal membranes. Among the numerous agents which are not typically amenable to oral administration are biologically or chemically active peptides, such as calcitonin and insulin; polysaccharides, and in particular mucopolysaccharides including, but not limited to, heparin; heparinoids; antibiotics; and other organic substances. These agents are  
10 rapidly rendered ineffective or are destroyed in the gastro-intestinal tract by acid hydrolysis, enzymes, and the like. In addition, the size and structure of macromolecular drugs may prohibit absorption.

Crossing the blood-brain barrier, as well as oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, mucosal, transdermal or pulmonary  
15 delivery to the circulatory system for many biologically active agents could be the route of choice for administration to animals if not for physical barriers such as the skin, lipid bi-layers, and various organ membranes that are relatively impermeable to certain biologically active agents, but one or more of which must be traversed before an agent delivered via these routes can reach the circulatory system. Additionally, delivery such as, for example, sublingual delivery may be  
20 impeded by chemical barriers such as the varying pH in the gastrointestinal (GI) tract and the presence of powerful digestive enzymes.

Earlier methods for orally administering vulnerable pharmacological agents have relied on the co-administration of adjuvants (e.g., resorcinols and non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecylpolyethylene ether) to increase artificially the  
25 permeability of the intestinal walls, as well as the co-administration of enzymatic inhibitors (e.g., pancreatic trypsin inhibitors, diisopropylfluorophosphate (DFF) and trasylol) to inhibit enzymatic degradation.

Liposomes have also been described as drug delivery systems for insulin and heparin. See, for example, U.S. Patent No. 4,239,754; Patel *et al.* (1976), *FEBS Letters*, Vol.  
30 62, pg. 60; and Hashimoto *et al.* (1979), *Endocrinology Japan*, Vol. 26, pg. 337.


However, broad spectrum use of such drug delivery systems is precluded because:  
(1) the systems require toxic amounts of adjuvants or inhibitors; (2) suitable low molecular weight cargos, i.e. active agents, are not available; (3) the systems exhibit poor stability and inadequate shelf life; (4) the systems are difficult to manufacture; (5) the systems fail to protect the active  
35 agent (cargo); (6) the systems adversely alter the active agent; or (7) the systems fail to allow or promote absorption of the active agent.

5 More recently, microspheres of artificial polymers of mixed amino acids (proteinoids) have been used to deliver pharmaceuticals. For example, U.S. Patent No. 4,925,673 describes drug-containing proteinoid microsphere carriers as well as methods for their preparation and use. These proteinoid microspheres are useful for the delivery of a number of active agents.

10 However, there is still a need for simple, inexpensive delivery systems which are easily prepared and which can deliver a broad range of active agents by various routes.

### SUMMARY OF THE INVENTION


The present invention provides compounds having the formula



20 and salts thereof. These compounds are useful in the delivery of active agents.

Another embodiment of the invention is a composition comprising:

- (A) at least one active agent; and
- (B) a carrier comprising a compound having the formula



30 or a salt thereof.

Also provided are dosage unit forms comprising the composition above and an excipient, a diluent, a disintegrant, a lubricant, a plasticizer, a colorant, a dosing vehicle, or any combination thereof.

35 Methods for administering a biologically-active agent to an animal in need of the

5 agent by the pulmonary, oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, rectal, vaginal, mucosal, transdermal, intradermal, parenteral, intravenous, or intramuscular route or crossing the blood-brain barrier with the compositions of the present invention are also provided.

## 10 **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a graphical illustration of blood glucose levels after pulmonary delivery of insulin.

Figure 2 is a graphical illustration of blood glucose levels after pulmonary delivery of insulin.

15

## **DETAILED DESCRIPTION OF THE INVENTION**

One group of compositions of the present invention include an active agent and a carrier which includes the compound 2-(4-(N-salicyloyl)aminophenyl)propionic acid or salts thereof, such as the sodium salt thereof (sodium 2-(4-(N-salicyloyl)aminophenyl)propionate).

20 These compositions may be used to deliver various active agents through various biological, chemical, and physical barriers and are particularly suited for delivering active agents which are subject to environmental degradation. The compositions of the subject invention are particularly useful for delivering or administering biologically or chemically active agents to any animals such as birds, including, but not limited to, chickens; mammals, such as primates, and particularly  
25 humans; and insects.

Other advantages of the present invention include the use of easy to prepare, inexpensive raw materials. The compositions and the formulation methods of the present invention are cost effective, simple to perform, and amenable to industrial scale up for commercial production.

30

Pulmonary, oral, subcutaneous, intranasal, sublingual, buccal, ocular, intracolonic, intraduodenal, rectal, vaginal, mucosal, transdermal, intradermal, parenteral, intravenous, and intramuscular coadministration of an active agent, such as, for example, recombinant human growth hormone (rhGH); salmon calcitonin; insulin heparin, including, but not limited to, low molecular weight heparin and very low molecular weight heparin; parathyroid hormone (PTH); and compounds  
35 in compositions as described herein result in an increased bioavailability of the active agent compared to administration of the active agent alone.

5

**Active Agents**


Active agents suitable for use in the present invention include biologically and chemically active agents including, but not limited to, cosmetics, pesticides, pharmacological agents, and therapeutic agents. For example, biologically or chemically active agents suitable for use in the present invention include, but are not limited to, proteins; polypeptides; peptides, and particularly small peptides; hormones, and particularly hormones which by themselves do not or only a fraction of the administered dose passes through the gastro-intestinal mucosa and/or are susceptible to chemical cleavage by acids and enzymes in the gastro-intestinal tract; polysaccharides, and particularly mixtures of much-polysaccharides; carbohydrates; lipids; other organic compounds; or any combination thereof. Further examples include, but are not limited to, the following, including synthetic, natural or recombinant sources thereof: growth hormones, including human growth hormones (hGH), recombinant human growth hormones (rhGH), bovine growth hormones, and porcine growth hormones; growth hormone-releasing hormones; interferons, including  $\alpha$ ,  $\beta$  and  $\gamma$ ; interleukin-1; interleukin-II; insulin; insulin-like growth factor, including IGF-1; heparin, including unfractionated heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular weight heparin and ultra low molecular weight heparin; calcitonin, including salmon, eel and human; erythropoietin (EPO); atrial natriuretic factor; antigens; monoclonal antibodies; somatostatin; protease inhibitors; adrenocorticotropin, gonadotropin releasing hormone; oxytocin; leutinizing-hormone-releasing-hormone; follicle stimulating hormone; glucocerebrosidase; thrombopoietin; filgrastim; prostaglandins; cyclosporin; vasopressin; cromolyn sodium (sodium or disodium chromoglycate); vancomycin; desferrioxamine (DFO); parathyroid hormone (PTH), including its fragments; antimicrobials, including anti-fungal agents; analogs, fragments, mimetics or polyethylene glycol (PEG)-modified derivatives of these compounds; or any combination thereof.

5

Carriers

The carrier compounds of the present invention include

10




2-(4-(N-salicyloyl)aminophenyl)propionic acid

15

and salts thereof. Salts of the compound include, but are not limited to, organic or inorganic salts, such as the sodium salt:

20



25

Sodium-2-(4-(N-salicyloyl)aminophenyl)propionate

In addition, carriers of the present invention include poly amino acids and peptides comprising one or more of the carrier compounds of the present invention.

30

These carrier compounds, poly amino acids, and peptides may be used to deliver active agents including, but not limited to, biologically or chemically active agents, such as for example, pharmacological and therapeutic agents.

An amino acid is any carboxylic acid having at least one free amine group and includes naturally occurring and synthetic amino acids.

35

Poly amino acids are either peptides or two or more amino acids linked by a bond formed by other groups which can be linked; e.g., an ester, anhydride, or an anhydride linkage.


Peptides are two or more amino acids joined by a peptide bond. Peptides can vary



5 in length from dipeptides with two amino acids to polypeptides with several hundred amino acids. See Chambers Biological Dictionary, editor Peter M.B. Walker, Cambridge, England: Chambers Cambridge, 1989, page 215. Special mention is made of di-peptides, tri-peptides, tetra-peptides, and penta-peptides.

The carriers described herein may be derived from amino acids and can be readily  
10 prepared from amino acids by methods within the skill of those in the art based upon the present disclosure and the methods described in WO96/30036, WO97/36480, US 5,643,957 and US 5,650,386. For example, the compounds may be prepared by reacting the single amino acid, mixtures of two or more amino acids, or amino acid esters with the appropriate acylating or amine-modifying agent, which reacts with a free amino moiety present in the amino acid to form amides.  
15 Protecting groups may be used to avoid unwanted side reactions as would be known to those skilled in the art. With regard to protecting groups, reference is made to T.W. Greene, Protecting Groups in Organic Synthesis, Wiley, New York (1981), the disclosure of which is hereby incorporated herein by reference.

Suitable, but not limiting, examples of acylating agents useful in preparing an  
20 acylated amino acids include the acid chloride acylating agents having the formula



25 wherein R<sup>1</sup> is an appropriate group for the modified amino acid being prepared, such as, but not limited to, alkyl, alkenyl, cycloalkyl, or aromatic, and particularly methyl, ethyl, cyclohexyl, cyclophenyl, phenyl, or benzyl, and X is a leaving group. Typical leaving groups include, but are not limited to, halogens such as chlorine, bromine and iodine.

Examples of the acylating agents include, but are not limited to, acyl halides  
30 including, but not limited to, acetyl chloride, propyl chloride, cyclohexanoyl chloride, cyclopentanoyl chloride, and cycloheptanoyl chloride, benzoyl chloride, hippuryl chloride and the like; and anhydrides, such as acetic anhydride, propyl anhydride, cyclohexanoic anhydride, benzoic anhydride, hippuric anhydride and the like. Preferred acylating agents include benzoyl chloride, hippuryl chloride, acetyl chloride, cyclohexanoyl chloride, cyclopentanoyl chloride, and cycloheptanoyl  
35 chloride.

The amine groups can also be modified by the reaction of a carboxylic acid with

5 coupling agents such as the carbodiimide derivatives of amino acids, particularly hydrophilic amino acids such as phenylalanine, tryptophan, and tyrosine. Further examples include dicyclohexylcarbodiimide and the like.

If the amino acid is multifunctional, i.e., has more than one -OH, -NH, or -SH group, then it may optionally be acylated at one or more functional groups to form, for example, an ester, amide, or thioester linkage.

For example, in the preparation of many acylated amino acids, the amino acids are dissolved in an aqueous alkaline solution of a metal hydroxide, e.g., sodium or potassium hydroxide and the acylating agent added. The reaction time can range from about 1 hour to about 4 hours, preferably about 2 to about 2.5 hours. The temperature of the mixture is maintained at a temperature generally ranging between about 5° C and about 70°C., preferably between about 10° C. and about 50°C. The amount of alkali employed per equivalent of NH<sub>2</sub> groups in the amino acids generally ranges between about 1.25 moles and about 3 moles, and is preferably between about 1.5 moles and about 2.25 moles per equivalent of NH<sub>2</sub>. The pH of the reaction solution generally ranges between about pH 8 and about pH 13, and is preferably between about pH 10 and about pH 12. The amount of amino modifying agent employed in relation to the quantity of amino acids is based on the moles of total free NH<sub>2</sub> in the amino acids. In general, the amino modifying agent is employed in an amount ranging between about 0.5 and about 2.5 mole equivalents, preferably between about 0.75 and about 1.25 equivalents, per molar equivalent of total NH<sub>2</sub> groups in the amino acids.

The modified amino acid formation reaction is typically quenched by adjusting the pH of the mixture with a suitable acid, e.g., concentrated hydrochloric acid, until the pH reaches between about 2 and about 3. The mixture separates on standing at room temperature to form a transparent upper layer and a white or off-white precipitate. The upper layer is discarded, and modified amino acids are collected by filtration or decantation. The crude modified amino acids are then mixed with water. Insoluble materials are removed by filtration, and the filtrate is dried in vacuo. The yield of modified amino acids generally ranges between about 30 and about 60%, and usually about 45%. The present invention also contemplates amino acids which have been modified by multiple acylation, e.g., diacylation, triacylation, etc.

If amino acid esters or amides are the starting materials, they are dissolved in a suitable organic solvent such as dimethylformamide or pyridine, and are reacted with the amino modifying agent at a temperature ranging between about 5°C. and about 70°C, preferably about 25°C, for a period ranging between about 7 and about 24 hours. The amount of amino modifying

5 agents used relative to the amino acid esters are the same as described above for amino acids.

Thereafter, the reaction solvent is removed under negative pressure, and optionally, the ester or amide functionality can be removed by hydrolyzing the modified amino acid ester with a suitable alkaline solution, e.g., 1N sodium hydroxide, at a temperature ranging between about 50°C, and about 80°C., preferably about 70°C., for a period of time sufficient to hydrolyze off the ester group and form the modified amino acid having a free carboxyl group. The hydrolysis mixture is then cooled to room temperature and acidified, e.g., with an aqueous 25% hydrochloric acid solution, to a pH ranging between about 2 and about 2.5. The modified amino acid precipitates out of solution and is recovered by conventional means such as filtration or decantation.

The modified amino acids may be purified by acid precipitation, recrystallization, or fractionation on one or more solid chromatographic supports, alone or linked in tandem. Suitable recrystallization solvent systems include, but are not limited to, acetonitrile, methanol, and tetrahydrofuran. Fractionation may be performed on a suitable chromatographic support such as silica gel or alumina, using solvent mixtures such as methanol/n-propanol mixtures or acetic acid/butanol/water mixtures as the mobile phase; reverse phase column supports using trifluoroacetic acid./acetonitrile mixtures as the mobile phase, and ion exchange chromatography using water as the mobile phase. When anion exchange chromatography is performed, preferably a 0-500 mM sodium chloride gradient is employed. The modified amino acids may also be purified by extraction with a lower alcohol such as methanol, butanol, or isopropanol to remove impurities such as inorganic salts.

25 The modified amino acids generally are soluble in alkaline aqueous solution (pH $\geq$ 9.0); partially soluble in ethanol, n-butanol and 1:1 (v/v) toluene/ethanol solution; and insoluble in neutral water. The alkali metal salts, e.g., the sodium salts of the modified amino acids, are generally soluble in water at about a pH of 6-8.

30 In poly amino acids or peptides, one or more of the amino acids may be modified acylated and/or sulfonated. Poly amino acids and peptides may include one or more acylated amino acid(s). Although linear modified poly amino acids and peptides will generally include only one acylated amino acid, other poly amino acid and peptide configurations can include more than one acylated amino acid. Poly amino acids and peptides can be polymerized with the acylated amino acid(s) or can be acylated after polymerization.

35

## 5     Delivery systems

The compositions of the present invention may include one or more active agents.

10     In one embodiment, the compounds above or salts of these compounds or poly amino acids or peptides that include at least one of these compounds or salts may be used directly as a delivery carrier by simply mixing one or more compounds or salts, poly amino acids or peptides with the active agent prior to administration.

15     The administration mixtures are prepared by mixing an aqueous solution of the carrier with an aqueous solution of the active ingredient, just prior to administration. Alternatively, the carrier and the biologically or chemically active ingredient can be admixed during the manufacturing process. The solutions may optionally contain additives such as phosphate buffer salts, citric acid, acetic acid, gelatin, and gum acacia.

20     Stabilizing additives may be incorporated into the carrier solution. With some drugs, the presence of such additives promotes the stability and dispersibility of the agent in solution. The stabilizing additives may be employed at a concentration ranging between about 0.1 and 5% (w/v), preferably about 0.5% (w/v). Suitable, but non-limiting examples of stabilizing additives include gum acacia, gelatin, methyl cellulose, polyethylene glycol, carboxylic acids and salts thereof, and polylysine. The preferred stabilizing additives are gum acacia, gelatin, and methyl cellulose.

25     The amount of active agent is an amount effective to accomplish the purpose of the particular active agent for the target indication. The amount of active agent in the compositions typically is a pharmacologically, biologically, therapeutically, or chemically effective amount. However, the amount can be less than a pharmacologically, biologically, therapeutically, or chemically effective amount when the composition is used in a dosage unit form, such as a capsule, a tablet, a powder, or a liquid, because the dosage unit form may contain a plurality of carrier/biologically or chemically active agent compositions of may contain a divided pharmacologically, biologically, therapeutically, or chemically effective amount. The total effective amount can then be administered in cumulative units containing, in total, pharmacologically, biologically, therapeutically or chemically active amounts of biologically or pharmacologically active agent.

30     The total amount of active agent, and particularly biologically or chemically active agent, to be used can be determined by those skilled in the art. However, it has surprisingly been found that with some biologically or chemically active agents, the use of the presently disclosed carriers provides extremely efficient delivery, particularly in oral, intranasal, sublingual,

5 intraduodenal, subcutaneous, buccal, intracolonic, rectal, vaginal, mucosal, pulmonary, transdermal, intradermal, parenteral, intravenous, intramuscular, and ocular systems, as well as traversing the blood-brain barrier. Therefore, lower amounts of biologically or chemically active agents than those used in prior dosage unit forms or delivery systems can be administered to the subject, while still achieving the same blood levels and therapeutic effects.

10 The amount of carrier in the present compositions is a delivery effective amount and can be determined for any particular carrier or biologically or chemically active agent by methods known to those skilled in the art. The effective amounts of the active agent and carrier in the composition may vary over a considerable range and is dependent upon the age, weight, sex, sensitivity, medical history, and the like of the individual. Clearly, it is necessary to take into  
15 account the nature of the active agent and carrier, the specific activity of the agent (units of bioactivity/mass), and its rate of absorption in the gastrointestinal tract, all of which contribute to a determination of the therapeutically effective dose.

Following administration, the active agent present in the composition or dosage unit form is rapidly taken up into the circulation. The bioavailability of the ingested agent is readily  
20 assessed by measuring a known pharmacological activity in blood, e.g. an increase in blood clotting time caused by heparin, or a decrease in circulating calcium levels caused by calcitonin.

Dosage unit forms can also include any of excipients, diluents, disintegrants, lubricants, plasticizers, colorants, flavorants, taste-masking agents, sugars, sweeteners, salts, and dosing vehicles, including, but not limited to water, 1,2-propane diol, ethanol, olive oil, or any  
25 combination thereof.

The delivery compositions of the present invention may also include one or more enzyme inhibitors. Such enzyme inhibitors include, but are not limited to, compounds such as actinonin or epiactinonin and derivatives thereof. Derivatives of these compounds are disclosed in U.S. Patent No. 5,206,384, the disclosure of which is hereby incorporated herein by reference. Other  
30 enzyme inhibitors include, but are not limited to, aprotinin (Trasylol) and Bowman-Birk inhibitor.

The system is particularly advantageous for delivering chemically or biologically active agents which would otherwise be destroyed or rendered less effective by conditions encountered before the active agent reaches its target zone (i.e. the area in which the active agent of the delivery composition is to be released) and within the body of the animal to which they are  
35 administered. Particularly, the present invention is useful in pulmonary administration, such as by an inhaler, of active agents, especially those which are not ordinarily deliverable by that route or

- 5 those for which improved delivery is desired. Improved delivery may be faster delivery or greater delivery in a given time period.

### **DESCRIPTION OF THE PREFERRED EMBODIMENTS**

- 10 The following examples illustrate the invention without limitation. All parts are given by weight unless otherwise indicated.

#### **Example 1 - Preparation of 2-(4-(N-salicyloyl)aminophenyl) propionic acid**

- A slurry of 58.6 g (0.355 mol) of 2-(4-aminophenyl)propionic acid and 500 ml of methylene chloride was treated with 90.11 ml (77.13 g, 0.710 mol) of trimethylsilyl chloride and was  
15 heated to reflux for 120 min. The reaction mixture was cooled to 0°C and treated with 184.44 ml (107.77 g, 1.065 mol) of triethylamine. After stirring for 5 minutes, this mixture was treated with a solution of 70.45 g (0.355 mol) of O-acetylsalicyloyl chloride and 150 ml of methylene chloride. The reaction mixture was warmed to 25°C and stirred for 64 hr. The volatiles were removed in vacuo. The residue was stirred in 2N aqueous sodium hydroxide for one hour and acidified with 2  
20 M aqueous sulfuric acid. The solid was recrystallized twice from ethanol/water to give a tan solid. Isolation by filtration afforded 53.05 g of (52% yield) of 2-(4-(N-salicyloyl)aminophenyl)propionic acid.

- Properties.** Solubility: 200 mg/ml: 200 mg + 350 µl 2N NaOH + 650 µl H<sub>2</sub>O - pH - 7.67. Anal. calculated for - C:67.36, H: 5.3, N: 4.91. Found - C: 67.05, H: 5.25, N: 4.72.

25

#### **Example 2 - Preparation of Sodium 2-(4-(N-salicyloyl)aminophenyl)propionate**

- A solution of 53.05 g (0.186 mol) of 2-(4-(N-salicyloyl)aminophenyl)propionic acid and 300 ml of ethanol was treated with 7.59 g (0.190 mol) of NaOH dissolved in 22 ml of water.  
30 The reaction mixture was stirred for 30 min at 25°C and for 30 min at 0°C. The resulting pale yellow solid was isolated by filtration to give 52.61 g of sodium 2-(4-(N-salicyloyl)aminophenyl)propionate.

- Properties.** Solubility: 200 mg/ml clear solution, pH=6.85. Anal. calculated for - C: 60.45, H: 5.45, N: 3.92, Na: 6.43. Found - C: 60.84, H: 5.87, N: 3.85, Na: 6.43. Melting point 236-238°C.

35

**5      Example 3**

A pulmonary delivery dosing composition of 0.1 mg/kg of porcine insulin and 7.5 mg/kg of the compound of Example 2 in water was prepared. A 0.3 ml/kg dose of the pulmonary dosing composition at pH 7.3-7.6 was administered to five normal, non-fasting rats by the following procedure. 1½ Popper and Sons gavage needles were inserted about a few centimeters down the  
10      animals' throats. The tip of the needle was manipulated towards the animals' ventral sides where the needle could fall into a pocket and then with further manipulation the trachea. Once the needle was in the trachea, the dosing solution was delivered through the needle.

Periodic blood samples were drawn via the tail artery, and blood glucose levels were measured using Ektachem DT slides (Johnson & Johnson Clinical Diagnostics, Inc., Rochester  
15      N.Y.).

Results are illustrated in Figure 1.

**Comparative Example 3A**

The procedure of Example 3 was followed, substituting a dosing composition of 0.1  
20      mg/kg of porcine insulin and water for the dosing composition.

Results are illustrated in Figure 1.

**Comparative Example 3B**

The procedure of Example 3 was followed, substituting a dosing solution of 7.5  
25      mg/kg of the compound prepared in Example 1 in water for the dosing solution.

Results are illustrated in Figure 1.

**Example 4**

The procedure of Example 3 was followed, substituting a dosing composition of 0.5  
30      mg/kg of porcine insulin and 7.5 mg/kg of the compound prepared in Example 2, in water for the dosing composition at pH 6.6-6.9.

Results are illustrated in Figure 2.

**Comparative Example 4A**

The procedure of Example 4 was followed, substituting a dosing composition of 0.5  
35      mg/kg of porcine insulin in water for the dosing composition.

5 Results are illustrated in Figure 2.

#### **Comparative Example 4B**

The procedure of Example 4 was followed, substituting a dosing composition of 7.5 mg/kg of the compound prepared in Example 2 in water for the dosing solution.

10 Results are illustrated in Figure 2.

#### **Example 5**

A dosing composition of 300 mg/kg of the compound prepared in Examples 2 and 3 mg/kg of human insulin in water at pH 7.02 was prepared. Strept catheterized rats were dosed by oral gavage with 1 ml/kg of the dosing composition. Blood glucose levels (mg/dL) were measured.

Results are illustrated in Table 1 below.

**Table 1**

Time (hrs):	0	0.5	1	2	3	4
Assay:	0	-44.9	-42.59	-37.58	36.62	-29.88
SD:	0	13.88	28.33	30.87	26.27	18.61

#### **Example 6**

A dosing composition of 300 mg/kg of the compound prepared in Example 1 and 100 Mg/kg of the N-terminal fragment of parathyroid hormone (amino acids 1-34) in water at pH 8.13 was prepared. Normal rats were dosed by oral gavage with 1 ml/kg of the dosing composition. Serum levels of parathyroid hormone (pg/mL) were measured.

Results are illustrated in Table 2 below.

**Table 2**

Time (mins):	0	15	30	45	60	90
Assay:	0	1522.53	886.5	786.46	711.6	482.46
SD:	0	538.5	272.21	239.78	181.65	329.78



**Example 7**

A dosing composition of 100 mg/kg of the compound prepared in Example 1 and 200 ug/kg of the N-terminal fragment of parathyroid hormone (amino acids 1-34) in water at pH 7.65 was prepared. Normal rats were dosed by oral gavage with 1 mg/kg of the dosing composition. Serum levels of parathyroid hormone (pg/mL) were measured.

Results are illustrated in Table 3 below.

**Table 3**

Time (mins):	0	15	30	45	60	90
Assay:	0	929.6	767.27	986.79	411.03	356.8
SD:	0	693.18	525.18	1211.9	136.15	61.13

**Example 8**

The method of Example 7 was followed but the pH of the dosing composition was 7.55.

Results are illustrated in Table 4 below.

**Table 4**

Time (min):	0	15	30	45	60	90
Assay:	0	976.79	711.42	610.78	520.51	516.19
SD:	0	388.07	244.89	218.16	78.31	37.6

**Example 9 - Pulmonary Insulin Delivery**

The carrier compound 2-(4-(N-salicyloyl)aminophenyl) propionic acid was tested as follows. Each rat was weighed and identified using an indelible marker and anesthetized by intramuscular injection of thorazine (3 mg/kg) and ketamine (44 mg/kg).

An endotracheal tube (spray instillator from Penn Century of Philadelphia, PA) with a syringe (Hamilton syringe) attached to the endotracheal tube was inserted using a fiber optic laryngoscope. The syringe (Hamilton syringe) of the instillator was used to instill insulin (0.03 mg/kg) and a carrier compound (16 mg/kg) into the lower portions of the airway. The endotracheal

5 tube was removed following administration, and the breathing rate was monitored throughout the remainder of the study.

Blood samples were withdrawn at 0, 5, 15, 30, 60, and 120 minutes via the tail artery and assayed with a DSL Insulin Kit #10-1600 following the procedure outlined in the kit. The  $C_{\max}$  value with the carrier was  $44.6 \pm 10.0$ . The  $C_{\max}$  value without the carrier was  $19.4 \pm 4.3$ .

10

#### **Example 10 - Recombinant Human Growth Hormone (rhGH) Oral Delivery**

Oral gavage (PO) dosing solutions containing 200 mg/kg carrier compound 2-(4-(N-salicyloyl)aminophenyl) propionic acid and 3 mg/kg rhGH in 100% phosphate buffer were prepared by mixing. The pH of the solutions ranged from about 7.67 to about 8.09.

15

Male Sprague-Dawley rats weighing 200-250 g were fasted for 24 hours and administered ketamine (44 mg/kg) and chlorpromazine (1.5 mg/kg) 15 minutes prior to dosing. The rats were administered 1 ml/kg of the dosing solution by PO. Blood samples were collected parenterally from the tail artery for determination of serum rhGH concentrations. Serum rhGH concentrations were quantified by an rhGH immunoassay test kit (Kit # K1F4015 from Genzyme Corporation Inc., Cambridge, MA). The mean peak serum concentration of rhGH was  $93 \pm 74$  ng/ml.

20

#### **Example 11 - Erythropoietin (EPO) Oral Delivery**

Oral gavage (PO) dosing solutions containing 200 mg/kg carrier compound 2-(4-(N-salicyloyl)aminophenyl) propionic acid and 1 mg/kg human erythropoietin quantikine IUD in 100% water were prepared by mixing. The pH of the solutions ranged from about 6.9 to about 7.9.

25

Male Sprague-Dawley rats weighing 200-250 g were fasted for 24 hours and administered ketamine (44 mg/kg) and chlorpromazine (1.5 mg/kg) 15 minutes prior to dosing. The rats were administered 1 ml/kg of the dosing solution by PO. Blood samples were collected parenterally from the tail artery for determination of serum EPO concentrations. Serum EPO concentrations were quantified by an Elisa assay test kit (Kit #DEPOO from R&D Systems, Minneapolis, MN). The mean peak serum concentration of EPO was  $163 \pm 136$  ng/ml.

30

The procedure was repeated without the carrier compound. The mean peak serum concentration of EPO was 0 ng/ml.

35


5           The above mentioned patents, applications, test methods, and publications are hereby incorporated by reference in their entirety.

          Many variations of the present invention will suggest themselves to those skilled in the art in light of the above detailed description. All such obvious variations are within the full intended scope of the appended claim.

10


WHAT IS CLAIMED IS:

1. A compound having the formula



or a salt thereof.

2. A composition comprising:
- (A) at least one active agent; and
- (B) a carrier comprising a compound having the formula



or a salt thereof.

3. A composition as defined in claim 2, wherein said active agent is selected from the group consisting of a biologically active agent, a chemically active agent, or a combination thereof.

4. A composition as defined in claim 3, wherein said biologically active agent comprises at least one peptide, mucopolysaccharide, carbohydrate, or lipid.

1                   5.       A composition as defined in claim 3, wherein said biologically active agent  
2       is selected from the group consisting of growth hormones, human growth hormones (hGH),  
3       recombinant human growth hormones (rhGH), bovine growth hormone, porcine growth hormones,  
4       growth hormone-releasing hormones, interferons,  $\alpha$ -interferon,  $\beta$ -interferon,  $\gamma$ -interferon,  
5       interleukin-1, interleukin-II; insulin, insulin-like growth factor(IGF), IGF-1, heparin, unfractionated  
6       heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular  
7       weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin,  
8       human calcitonin, erythropoietin (EPO), atrial naturetic factor, antigens, monoclonal antibodies,  
9       somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin,  
10      leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase,  
11      thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, sodium chromoglycate,  
12      disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH),  
13      fragments of PTH, antimicrobials, anti-fungal agents, analogs, fragments, mimetics and polyethylene  
14      glycol (PEG)-modified derivatives of these compounds; and any combination thereof.

1                   6.       A composition as defined in claim 3, wherein said biologically active agent  
2       is selected from the group consisting of human growth hormones (hGH), bovine growth hormone,  
3       growth hormone-releasing hormones, interferons, interleukin-1, interleukin-II, insulin, heparin, low  
4       molecular weight heparin, very low molecular weight heparin, calcitonin, erythropoietin (EPO),  
5       atrial naturetic factor, antigens, monoclonal antibodies, somatostatin, adrenocorticotropin,  
6       gonadotropin releasing hormone, oxytocin, vasopressin, sodium chromoglycate, disodium  
7       chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials,  
8       anti-fungal agents, and any combination thereof.

1                   7.       A composition as defined in claim 3, wherein said biologically active agent  
2       comprises an interferon, interleukin-II, insulin, heparin, low molecular weight heparin, very low  
3       molecular weight heparin, calcitonin, parathyroid hormone (PTH), erythropoietin (EPO), human  
4       growth hormone (hGH), oxytocin, vasopressin, vancomycin, desferrioxamine (DFO), parathyroid  
5       hormone, and combinations thereof.

1                   8.       A composition as defined in claim 3, wherein said biologically active agent  
2       comprises unfractionated heparin, ultra low molecular weight heparin, and combinations thereof.

1                   9.     A composition as defined in claim 3, wherein said biologically active agent  
2 comprises insulin.

1                   10.    A composition as defined in claim 3, wherein said biologically active agent  
2 comprises parathyroid hormone.

1                   11.    A composition as defined in claim 3, wherein said biologically active agent  
2 comprises human growth hormone.

1                   12.    A composition as defined in claim 3, wherein said biologically active agent  
2 comprises erythropoietin.

1                   13.    A composition as defined in claim 2, wherein said carrier comprises a  
2 poly(amino acid) or a polypeptide.

1                   14.    A dosage unit form comprising:  
2 (A)   a composition as defined in claim 2; and  
3 (B)   (a)    an excipient  
4       (b)    a diluent,  
5       (c)    a disintegrant,  
6       (d)    a lubricant,  
7       (e)    a plasticizer,  
8       (f)    a colorant,  
9       (g)    a dosing vehicle, or  
10      (h)    any combination thereof.

1                   15.    A dosage unit form as defined in claim 13, wherein said active agent is  
2 selected from the group consisting of a biologically active agent, a chemically active agent, or a  
3 combination thereof.

1                   16.    A dosage unit form as defined in claim 14, wherein said biologically active

2 agent comprises at least one peptide, mucopolysaccharide, carbohydrate, or lipid.

1 17. A dosage unit form as defined in claim 14, wherein said biologically active  
2 agent is selected from the group consisting of growth hormones, human growth hormones (hGH),  
3 recombinant human growth hormones (rhGH), bovine growth hormone, porcine growth hormones,  
4 growth hormone-releasing hormones, interferons,  $\alpha$ -interferon,  $\beta$ -interferon,  $\gamma$ -interferon,  
5 interleukin-1, interleukin-II, insulin, insulin-like growth factor(IGF), IGF-1, heparin, unfractionated  
6 heparin, heparinoids, dermatans, chondroitins, low molecular weight heparin, very low molecular  
7 weight heparin, ultra low molecular weight heparin, calcitonin, salmon calcitonin, eel calcitonin,  
8 human calcitonin, erythropoietin (EPO), atrial natriuretic factor, antigens, monoclonal antibodies,  
9 somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin,  
10 leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase,  
11 thrombopoietin, filgrastim, prostaglandins, cyclosporin, vasopressin, sodium chromoglycate,  
12 disodium chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH),  
13 fragments of PTH, antimicrobials, anti-fungal agents, analogs, fragments, mimetics and polyethylene  
14 glycol (PEG)-modified derivatives of these compounds, and any combination thereof.

1 18. A dosage unit form as defined in claim 14, wherein said biologically active  
2 agent is selected from the group consisting of human growth hormones (hGH), bovine growth  
3 hormone, growth hormone-releasing hormones, interferons, interleukin-1, interleukin-II, insulin,  
4 heparin, low molecular weight heparin, very low molecular weight heparin, calcitonin, erythropoietin  
5 (EPO), atrial natriuretic factor, antigens, monoclonal antibodies, somatostatin, adrenocorticotropin,  
6 gonadotropin releasing hormone, oxytocin, vasopressin, sodium chromoglycate, disodium  
7 chromoglycate, vancomycin, desferrioxamine (DFO), parathyroid hormone (PTH), antimicrobials,  
8 anti-fungal agents, and any combination thereof.

1 19. A dosage unit form as defined in claim 14, wherein said biologically active  
2 agent comprises an interferon, interleukin-II, insulin, heparin, low molecular weight heparin, very  
3 low molecular weight heparin, calcitonin, parathyroid hormone (PTH), erythropoietin (EPO), human  
4 growth hormone (hGH), oxytocin, vasopressin, vancomycin, desferrioxamine (DFO), parathyroid  
5 hormone, and combinations thereof.

1                   20.    A dosage unit form as defined in claim 14, wherein said biologically active  
2   agent comprises unfractionated heparin, ultra low molecular weight heparin, and combinations  
3   thereof.

1                   21.    A dosage unit form as defined in claim 14, wherein said biologically active  
2   agent comprises insulin.

1                   22.    A dosage unit form as defined in claim 14, wherein said biologically active  
2   agent comprises parathyroid hormone.

1                   23.    A dosage unit form as defined in claim 14, wherein said biologically active  
2   agent comprises human growth hormone.

1                   24.    A dosage unit form as defined in claim 14, wherein said biologically active  
2   agent comprises erythropoietin.

1                   25.    A dosage unit form as defined in claim 13, comprising a tablet, a powder, a  
2   capsule, or a liquid.


1                   26.    A method for administering a biologically-active agent to an animal in need  
2   of said agent, said method comprising administering orally to said animal a composition as defined  
3   in claim 3.


1                   27.    A method for preparing a composition comprising mixing:  
2                   (A)    at least one active agent;  
3                   (B)    the compound of claim 1; and  
4                   (C)    optionally, a dosing vehicle.



1/2

Figure 1





# INTERNATIONAL SEARCH REPORT

Intern al Application No

PCT/US 99/17090

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 C07C235/64 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PICCIOLA G: "SINTESI DI ACIDI CHINAZOLINONICI E BENZOSSAZINONICI E STUDIO DELLE LORO PROPRIETA ANTIINFIAMMATORIE" FARMACO, EDIZIONE SCIENTIFICA, IT, SOCIETA CHIMICA ITALIANA, PAVIA, vol. 31, no. 9, page 655-664 XP002045209 page 662; table III	1
Y	page 662; table III	1-27
Y	WO 96 30036 A (EMISPHERE TECH INC ; LEONE BAY ANDREA (US); HO KOC KAN (US); SARUBB) 3 October 1996 (1996-10-03) page 1 -page 22; claims 1,2,11-29	1-27
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A" document member of the same patent family

Date of the actual completion of the international search

12 November 1999

Date of mailing of the international search report

19/11/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3018

Authorized officer

Rufet, J

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/17090

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 36480 A (EMISPHERE TECHNOLOGIES INC ;LEONE BAY ANDREA (US)) 9 October 1997 (1997-10-09) pages 1-3; page 9, line 19; pages 47 to 50; claims -----	1-27
Y	LEONE-BAY A ET AL: "4-(4-((2-HYDROXYBENZOYL)AMINOPHENYL)BUTYRI C ACID AS A NOVEL ORAL DELIVERY AGENT FOR RECOMBINANT HUMAN GROWTH HORMONE" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 39, no. 13, 1996, page 2571-2578 XP002914793 ISSN: 0022-2623 page 2577, paragraph 3; figure 7; tables 1,2 -----	1-27

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/17090

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 26 and 27  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Application No

PCT/US 99/17090

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9630036 A	03-10-1996	US 5650386 A	22-07-1997
		AU 5662996 A	16-10-1996
		BR 9604880 A	19-05-1998
		CA 2214323 A	03-10-1996
		CN 1190893 A	19-08-1998
		CZ 9703073 A	18-03-1998
		EP 0817643 A	14-01-1998
		FI 973828 A	29-09-1997
		HU 9901162 A	30-08-1999
		NO 974495 A	28-11-1997
		NZ 307319 A	28-10-1999
		PL 322494 A	02-02-1998
		US 5965121 A	12-10-1999
		US 5866536 A	02-02-1999
WO 9736480 A	09-10-1997	AU 2595697 A	22-10-1997
		EP 0817643 A	14-01-1998
		SI 9720025 A	31-08-1999